Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

Sarah A. Taylor, Dorothy J. Giroux, Kurt A. Jaeckle, Timothy J. Panella, Shaker R. Dakhil, S. Clifford Schold

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

Original languageEnglish (US)
Pages (from-to)331-332
Number of pages2
JournalInvestigational New Drugs
Volume16
Issue number4
DOIs
StatePublished - Dec 1 1998

Keywords

  • Central nervous system tumors
  • Didemnin B

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Taylor, S. A., Giroux, D. J., Jaeckle, K. A., Panella, T. J., Dakhil, S. R., & Schold, S. C. (1998). Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study. Investigational New Drugs, 16(4), 331-332. https://doi.org/10.1023/A:1006273214056